Use of tafenoquine to treat a patient with relapsing babesiosis with clinical and molecular evidence of resistance to azithromycin and atovaquone

Tafenoquine is a highly effective treatment for Babesia microti infections in animal models. An immunocompromised patient infected by a strain of B. microti that was at least partially resistant to both azithromycin and atovaquone was treated with tafenoquine. Systematic clinical studies using tafen...

Descripción completa

Detalles Bibliográficos
Autores principales: Marcos, Luis A., Leung, Annie, Kirkman, Laura, Wormser, Gary P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885462/
https://www.ncbi.nlm.nih.gov/pubmed/35242564
http://dx.doi.org/10.1016/j.idcr.2022.e01460
_version_ 1784660425884827648
author Marcos, Luis A.
Leung, Annie
Kirkman, Laura
Wormser, Gary P.
author_facet Marcos, Luis A.
Leung, Annie
Kirkman, Laura
Wormser, Gary P.
author_sort Marcos, Luis A.
collection PubMed
description Tafenoquine is a highly effective treatment for Babesia microti infections in animal models. An immunocompromised patient infected by a strain of B. microti that was at least partially resistant to both azithromycin and atovaquone was treated with tafenoquine. Systematic clinical studies using tafenoquine for treating other patients with babesiosis should be considered.
format Online
Article
Text
id pubmed-8885462
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-88854622022-03-02 Use of tafenoquine to treat a patient with relapsing babesiosis with clinical and molecular evidence of resistance to azithromycin and atovaquone Marcos, Luis A. Leung, Annie Kirkman, Laura Wormser, Gary P. IDCases Case Report Tafenoquine is a highly effective treatment for Babesia microti infections in animal models. An immunocompromised patient infected by a strain of B. microti that was at least partially resistant to both azithromycin and atovaquone was treated with tafenoquine. Systematic clinical studies using tafenoquine for treating other patients with babesiosis should be considered. Elsevier 2022-02-25 /pmc/articles/PMC8885462/ /pubmed/35242564 http://dx.doi.org/10.1016/j.idcr.2022.e01460 Text en © 2022 Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Marcos, Luis A.
Leung, Annie
Kirkman, Laura
Wormser, Gary P.
Use of tafenoquine to treat a patient with relapsing babesiosis with clinical and molecular evidence of resistance to azithromycin and atovaquone
title Use of tafenoquine to treat a patient with relapsing babesiosis with clinical and molecular evidence of resistance to azithromycin and atovaquone
title_full Use of tafenoquine to treat a patient with relapsing babesiosis with clinical and molecular evidence of resistance to azithromycin and atovaquone
title_fullStr Use of tafenoquine to treat a patient with relapsing babesiosis with clinical and molecular evidence of resistance to azithromycin and atovaquone
title_full_unstemmed Use of tafenoquine to treat a patient with relapsing babesiosis with clinical and molecular evidence of resistance to azithromycin and atovaquone
title_short Use of tafenoquine to treat a patient with relapsing babesiosis with clinical and molecular evidence of resistance to azithromycin and atovaquone
title_sort use of tafenoquine to treat a patient with relapsing babesiosis with clinical and molecular evidence of resistance to azithromycin and atovaquone
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885462/
https://www.ncbi.nlm.nih.gov/pubmed/35242564
http://dx.doi.org/10.1016/j.idcr.2022.e01460
work_keys_str_mv AT marcosluisa useoftafenoquinetotreatapatientwithrelapsingbabesiosiswithclinicalandmolecularevidenceofresistancetoazithromycinandatovaquone
AT leungannie useoftafenoquinetotreatapatientwithrelapsingbabesiosiswithclinicalandmolecularevidenceofresistancetoazithromycinandatovaquone
AT kirkmanlaura useoftafenoquinetotreatapatientwithrelapsingbabesiosiswithclinicalandmolecularevidenceofresistancetoazithromycinandatovaquone
AT wormsergaryp useoftafenoquinetotreatapatientwithrelapsingbabesiosiswithclinicalandmolecularevidenceofresistancetoazithromycinandatovaquone

Ejemplares similares